SCHEMBL6185529

SCHEMBL6185529

COc1cc(S[C@@H](C[C@@H](N)CO)c2ccccc2)c(C#N)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.40
SLC6A2 P23975 4/20 0.40
SLC6A4 P31645 4/20 0.40
NOS2 P35228 4/20 0.40
AAK1 Q2M2I8 2/20 0.36
CYP3A4 P08684 1/20 0.36
P2RX3 P56373 3/20 0.33
P2RX2 Q9UBL9 3/20 0.33
MPO P05164 1/20 0.32
PLK1 P53350 1/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
ALDH1A1 P00352 2/20 0.31
AR P10275 2/20 0.31
USP2 O75604 1/20 0.31
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KIF11 P52732 2/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231183 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL6750050 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL6746295 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL231181 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL6187189 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL231182 1.00 CYP2D6 (0.40) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL6746353 0.91 CYP2D6 (0.39) CYP2D6SLC6A2SLC6A4NOS2MPO
SCHEMBL6188753 0.89 CYP2D6 (0.42) CYP2D6SLC6A2SLC6A4NOS2AAK1
SCHEMBL6748041 0.88 CYP2D6 (0.39) CYP2D6SLC6A2SLC6A4NOS2MPO
SCHEMBL6189092 0.86 CYP3A4 (0.34) CYP2D6SLC6A2SLC6A4NOS2AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572655-A2 NOVEL ARYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2005-09-14 EP claimed
US-20040242871-A1 Novel arylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2004-12-02 US claimed
WO-2002090332-A2 NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES ASTRAZENECA AB (SE) 2002-11-14 WO claimed
US-20040242871-A1 Novel arylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242871-A1 Novel arylheteroalkylamine derivatives CYP1A1, NOS3, NOS1 CYP2D6 48/4885SLC6A2 2580/4885SLC6A4 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.